je.st
news
Tag: study results
Ohio States Dr. Nicholas Basta Presents Results of Independent Research Study on ECOBOND Paint
2018-07-25 19:28:00| Coatings World Breaking News
At the International Conference for Heavy Metals in the Environment.
Tags: results
research
states
study
Results from Iowa Waste Characterization Study Jump-Start Diversion Conversations
2018-01-18 17:17:33| Waste Age
Research from the Iowa Department of Natural Resources shows potential for high diversion.
Tags: results
study
waste
iowa
ITF shared mobility study for Helsinki bolsters other results suggesting car sharing ends congestion, cuts emissions
2017-10-25 11:55:40| Green Car Congress
Tags: results
car
study
sharing
Interim Results from Phase 1b/2 Study Evaluating the Combination of Mercks KEYTRUDA (pembrolizumab) and Eisais HALAVEN (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 SABCS
2016-12-12 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & WOODCLIFF LAKE, N.J. KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new interim data investigating Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with Eisais microtubule dynamics inhibitor, HALAVEN (eribulin), in patients with metastatic triple-negative breast cancer (TNBC). Language: English Contact: Media:MerckPamela Eisele, 267-305-3558orKim Hamilton, (908) 740-1863orEisai Inc.Laurie Landau, 201-746-2510orInvestors:MerckTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898orEisai Inc.Ivor Macleod, 201-746-2660 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: results
study
presented
combination
Results from Mercks Phase 3 Study Evaluating ZEPATIER (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine
2016-08-08 23:05:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6 infection receiving opioid agonist therapy (OAT) (methadone and buprenorphine), commonly used to treat opioid addiction. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more